Type 1 diabetes is characterized by the loss of pancreatic beta cells, which leads to absolute insulin deficiency. It accounts for 5-10% of diabetes cases in the United states.1 Treatment of type 1 diabetes usually involves coordination of meals and carbohydrate intake along with insulin replacement. Type 2 diabetes is characterized by hyperglycemia and insulin resistance, with some impairment to insulin secretion. Treatment options include oral therapy, injectable therapy, as well as insulin products.
GLP-1 RA: Glucagon-like peptide-1 receptor agonist
SGLT2: Sodium/glucose linked transporter inhibitor
DPP4: Dipeptidyl peptidase-4 inhibitor
ASCVD: Atherosclerotic cardiovascular disease
CKD: Chronic kidney disease
HF: Heart failure
In order to further improve the care for those within our network, Affinia Health Network is participating in a statewide collaboration to specifically improve diabetes care. Our goal is to provide primary care clinicians with evidence-based guidance on type 2 diabetes management to improve quality of care, reduce inappropriate (or inefficient) use of pharmaceuticals and lower the cost of care. This collaboration will analyze data, identify opportunities, and develop workflows and interventions to further improve care. For more information, please contact the Affinia Health Network Pharmacy Department at AffiniaPharmacy@mercyhealth.com.